| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-83940-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-526-0.025ml | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-49644SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-51843SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-88861-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-92273-25ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| IHC-Prediluted | NBP2-44585 | |||
| Azide and BSA Free | NBP2-34816-0.1mg | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| Azide and BSA Free | NBP2-33074 | |||
| IHC-Prediluted | NBP2-44976 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-54153SS | |||
![Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0076.jpg "Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (5, 15 and 50 ug) from 293T cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit antiP53 antibody used for WB at0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.")
![Immunohistochemistry-Paraffin: p53 Antibody [NB200-171] - FFPE section of human lung cancer Antibody: Affinity purified rabbit anti- p53 used at 1:5,000 (0.2ug/ml). Detection: DAB](http://images.novusbio.com/fullsize/p53-Antibody-Immunohistochemistry-Paraffin-NB200-171-img0075.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - p53 in Jurkat Cells, fixed in 1.5% PFA, and permeabilized in 90% Methanol. 1 million cells were stained with 1.5 ug anti-KLH IgG control or anti-p53 NB200-171 and secondary FITC-conjugated goat anti-rabbit (in a 150ul reaction). Black- anti-KLH control IgG; Red- anti-HDMX.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0002.jpg)
![Chromatin Immunoprecipitation Sequencing: p53 Antibody [NB200-171] - Chromatin from MCF7 was immunoprecipitated with anti-p53 antibody and analyzed by DNA sequencing. The figure illustrates the peak distribution of p53 binding within a 250 Kb region of chromosome 6 as detected using anti-p53. ChIP-seq validation performed by Active Motif, Carlsbad, CA.](http://images.novusbio.com/fullsize/p53-Antibody-Chromatin-Immunoprecipitation-Sequencing-NB200-171-img0073.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: p53 Antibody [NB200-171] - Whole cell lysate (100 ug) from 293T cells that were treated with an siRNA for p53 (+) or mock treated (-). Antibody used at the indicated concentrations.](http://images.novusbio.com/fullsize/p53-Antibody-Western-Blot-NB200-171-img0003.jpg)
![Flow Cytometry: p53 Antibody [NB200-171] - Baseline p53 expression in human lymphocytes. Image from verified customer review.](http://images.novusbio.com/fullsize/p53-Antibody-Flow-Cytometry-NB200-171-img0004.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: p53 Antibody [NB200-171] - Detection of human P53 by western blot of immunoprecipitates. Samples: Whole cell lysate (1.0 mg per IP reaction; 20% of IP loaded) from HEK293T cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-P53 antibody NB200-171 used for IP at 3 ug per reaction. P53 was also immunoprecipitated by rabbit anti-P53 antibody NB100-2204. For blotting immunoprecipitated P53, NB200-171 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 30 seconds.](http://images.novusbio.com/fullsize/p53-Antibody-Immunoprecipitation-NB200-171-img0077.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining in human skin and pancreas tissues. Corresponding KLF4 RNA-seq data are presented for the same tissues.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0021.jpg "<b>Orthogonal Strategies Validation. </b>Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining in human skin and pancreas tissues. Corresponding KLF4 RNA-seq data are presented for the same tissues.")
![Immunocytochemistry/Immunofluorescence: KLF4 Antibody [NBP1-83940] - Staining of human cell line A-431 shows localization to nucleoplasm. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-83940-img0009.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: KLF4 Antibody [NBP1-83940] - Human breast cancer cell MCF-7 was treated with carboplatin, alone or in combination with Stat3 inhibitor, for 72 hours, and the expression of Klf4 was detected by Western blot. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0022.jpg)
![Western Blot: KLF4 Antibody [NBP1-83940] - Analysis in control (vector only transfected HEK293T lysate) and KLF4 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0023.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: KLF4 Antibody [NBP1-83940] - MDA-MB-231 subclones transfected with NTC or HIF-1 alpha shRNA vector were treated with vehicle (V) or paclitaxel (P) and immunoblot assay was performed. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/KLF4-Antibody-Western-Blot-NBP1-83940-img0024.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human colon shows moderate to strong nuclear positivity in glandular cells.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0017.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human pancreas shows no positivity in exocrine glandular cells as expected.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0018.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human skin shows moderate to strong nuclear positivity in keratinocytes.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0019.jpg)
![Immunohistochemistry-Paraffin: KLF4 Antibody [NBP1-83940] - Staining of human testis shows moderate to strong nuclear positivity in a subset of cells in seminiferous ducts.](http://images.novusbio.com/fullsize/KLF4-Antibody-Immunohistochemistry-Paraffin-NBP1-83940-img0020.jpg)
![Western Blot: KLF4 Antibody [NBP1-83940] - HIFs are required for hypoxia-induced expression of pluripotency factorsA-C. Breast cancer cell lines were exposed to 20% or 1% O2 for 24 h & NANOG (A), KLF4 (B), & SOX2 (C) mRNA levels were determined by RT-qPCR, relative to 18S rRNA, & normalized to the mean value for MDA-MB-231 cells (MDA231) at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. same cell line at 20% O2 by Student's t test. D & E. HCC-1954 (D) & MCF-7 (E) subclones, which were stably transfected with an expression vector encoding a non-targeting control (NTC) shRNA, or vector encoding shRNA targeting HIF-1 alpha (sh1 alpha ) or HIF-2 alpha (sh2 alpha ), or vectors encoding shRNAs targeting both HIF-1 alpha & HIF-2 alpha (DKD), were exposed to 20% or 1% O2 for 24 h & RT-qPCR was performed to determine NANOG (D) or KLF4 (E) mRNA levels relative to 18S rRNA. The results were normalized to NTC at 20% O2 (mean ± SEM; n = 3). *P < 0.05, **P < 0.01, ***P < 0.001 vs. NTC at 20% O2; #P < 0.05, ##P < 0.01, ###P < 0.001 vs. NTC at 1% O2 by ANOVA. F. ZR75.1 cells treated with vehicle or digoxin (200 nM) were exposed to 20% or 1% O2 for 24 h & SOX2 mRNA was measured (mean ± SEM; n = 3). *P < 0.05, **P < 0.01 vs. NTC at 20% O2; ###P < 0.001 vs. NTC at 1% O2 by ANOVA. G & H. NTC & DKD subclones of HCC-1954 (G) & MCF-7 (H) were exposed to 20% or 1% O2 for 48 h, whole cell lysates were prepared, & immunoblot assays were performed to analyze HIF-1 alpha , HIF-2 alpha , NANOG & KLF4 protein expression. Actin was also analyzed as a loading control. I. ZR75.1 cells were treated with vehicle or digoxin (200 nM), exposed to 20% or 1% O2 for 48 h, & HIF-1 alpha , NANOG & SOX2 immunoblot assays were performed. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.11743), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-83940_rabbit-polyclonal-klf4-antibody-310202416121929.jpg)
![Western Blot: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of 25 ug of PC12 cell lysates.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Western-Blot-NB300-526-img0018.jpg "Western Blot: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of 25 ug of PC12 cell lysates.")
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of Hela cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0015.jpg)
![Immunohistochemistry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Immunolocalization of ET-1 in human bowel.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunohistochemistry-NB300-526-img0017.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in 3T3 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0012.jpg)
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of PC12 cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 (green) showing positive staining in the secretion of HUVEC cells (right) compared with a negative control in the absence of primary antibody (left).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunocytochemistry-Immunofluorescence-NB300-526-img0014.jpg)
![Immunohistochemistry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Immunolocalization of ET-1 in human bowel.](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Immunohistochemistry-NB300-526-img0016.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in HepG2 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0006.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in 293T cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0007.jpg)
![Flow Cytometry: Endothelin-1 Antibody (TR.ET.48.5) [NB300-526] - Analysis of Endothelin 1 in HepG2 cells compared to an isotype control (blue).](http://images.novusbio.com/fullsize/Endothelin-1-Antibody-TR-ET-48-5-Flow-Cytometry-NB300-526-img0011.jpg)
![Western Blot: USP22 Antibody [NBP1-49644] - Western blot analysis of Usp22 in HeLa whole cell extracts.](http://images.novusbio.com/fullsize/USP22-Antibody-Western-Blot-NBP1-49644-img0001.jpg "Western Blot: USP22 Antibody [NBP1-49644] - Western blot analysis of Usp22 in HeLa whole cell extracts.")
![Western Blot: USP22 Antibody [NBP1-49644] - analysis of USP22 in HeLa whole cell lysate using anti-USP22 antibody. The primary antibody was used at a dilution of 1:500 and incubated overnight at 4C. Image from verified customer review.](http://images.novusbio.com/fullsize/USP22-Antibody-Western-Blot-NBP1-49644-img0002.jpg)
![Simple Western: USP22 Antibody [NBP1-49644] - Simple Western lane view shows a specific band for USP22 in 1.0 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/USP22-Antibody-Simple-Western-NBP1-49644-img0003.jpg)
![Simple Western: Ki67/MKI67 Antibody [NBP2-19012] - Detection of Ki67/MKI67 by Simple WesternTM. Simple Western lane view shows lysates of HeLa parental cell line and Ki67 knockout (KO) HeLa cell line. A specific band was detected for Ki67/MKI67 at approximately 312 kDa (as indicated) in the parental cell line, but is not detectable in the knockout HeLa cell line using 20 ug/mL of Rabbit Anti-Ki67/MKI67 Polyclonal Antibody (Catalog # NBP2-19012). GAPDH is shown as a loading control. This experiment was conducted under reducing conditions and using the 66-440 kDa separation system.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Knockout-Validated-NBP2-19012-img0009.jpg "<b>Genetic Strategies Validation. </b>Simple Western: Ki67/MKI67 Antibody [NBP2-19012] - Detection of Ki67/MKI67 by Simple WesternTM. Simple Western lane view shows lysates of HeLa parental cell line and Ki67 knockout (KO) HeLa cell line. A specific band was detected for Ki67/MKI67 at approximately 312 kDa (as indicated) in the parental cell line, but is not detectable in the knockout HeLa cell line using 20 ug/mL of Rabbit Anti-Ki67/MKI67 Polyclonal Antibody (Catalog # NBP2-19012). GAPDH is shown as a loading control. This experiment was conducted under reducing conditions and using the 66-440 kDa separation system.")
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Ki67/MKI67 Antibody [NBP2-19012] - A431 cells were fixed in 4% paraformaldehyde for 10 minutes and permeabilized in 0.5% Triton X-100 in PBS for 5 minutes. The cells were incubated with anti- NBP2-19012 at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19012-img0010.jpg)
![Western Blot: Ki-67/MKI67 Antibody [NBP2-19012] - Analysis of A431 (A), HeLa (B), Ntera2 (C), and HEK293 (D) cell lysate using Ki67 antibody (NBP2-19012) at 2 ug/ml.](http://images.novusbio.com/fullsize/Ki67-Antibody-Western-Blot-NBP2-19012-img0006.jpg)
![Immunohistochemistry-Paraffin: Ki-67/MKI67 Antibody [NBP2-19012] - Human breast tumor stained with Ki-67 antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.](http://images.novusbio.com/fullsize/Ki67-Antibody-Immunohistochemistry-Paraffin-NBP2-19012-img0003.jpg)
![Flow Cytometry: Ki-67/MKI67 Antibody [NBP2-19012] - Expression in actively growing Jurkat cells: Cells were stained with 0.2 ug of Ki-67 antibody (red) and isotype control (green) and positively stained population was identified using PE conjugated goat anti-rabbit IgG secondary antibody. Cells fixed and permeabilized using ice cold 70% ethanol were used in this intracellular staining protocol.](http://images.novusbio.com/fullsize/Ki67-Antibody-Flow-Cytometry-NBP2-19012-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: Ki-67/MKI67 Antibody [NBP2-19012] - Ki67 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red). Image objective 40x. An antibody dilution of 1:10 was used.](http://images.novusbio.com/fullsize/Ki67-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19012-img0008.jpg)
![<b>Genetic Strategies Validation. </b>Knockdown Validated: Ki67/MKI67 Antibody [NBP2-19012] - Cell proliferation of BCa cells treated by SIRT1-target-specific-siRNA (B) and negative-control-siRNA (A) was assayed by Ki-67 staining (green). Nuclei (blue) were stained by DAPI. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/29147649/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Ki67-MKI67-Antibody-Immunocytochemistry-Immunofluorescence-NBP2-19012-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti- (NBP1-51843) at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution overnight at 4C and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-51843-img0012.jpg "Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - HeLa cells were fixed and permeabilized for 10 minutes using -20C MeOH. The cells were incubated with anti- (NBP1-51843) at 2 ug/ml overnight at 4C and detected with an anti-rabbit Dylight 488 (Green) at a 1:1000 dilution for 60 minutes. Alpha tubulin (DM1A) NB100-690 was used as a co-stain at a 1:1000 dilution overnight at 4C and detected with an anti-mouse Dylight 550 (Red) at a 1:1000 dilution for 60 minutes. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 100X objective and digitally deconvolved.")
![Simple Western: Aurora A Antibody [NBP1-51843] - Simple Western lane view shows a specific band for Aurora A in 0.5 mg/ml of HeLa lysate. This experiment was performed under reducing conditions using the 12-230kDa separation system.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Simple-Western-NBP1-51843-img0010.jpg)
![Immunocytochemistry/Immunofluorescence: Aurora A Antibody [NBP1-51843] - IF Confocal analysis of HeLa cells using Aurora A antibody (NBP1-51843, 1:10). An Alexa Fluor 488-conjugated Goat to rabbit IgG was used as secondary antibody (green). Actin filaments were labeled with Alexa Fluor 568 phalloidin (red). DAPI was used to stain the cell nuclei (blue).](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-51843-img0008.jpg)
![Western Blot: Aurora A Antibody [NBP1-51843] - WB detection of Aurora A in HeLa whole cell lysate.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Western-Blot-NBP1-51843-img0011.jpg)
![Immunohistochemistry: Aurora A Antibody [NBP1-51843] - IHC staining of Aurora A in mouse brain.](http://images.novusbio.com/fullsize/Aurora-A-Antibody-Immunohistochemistry-NBP1-51843-img0003.jpg)
![Simple Western: Aurora A Antibody - BSA Free [NBP1-51843] - Analysis of protein expression post-drug treatment. (A) CHLA-10 and (B) TC-71 cells treated with drugs were assessed for changes in protein expression 24 h post-treatment via capillary electrophoresis-based Wes analysis. Increased protein levels of KIF11, p-KIF11Thr926 AURKA, and p-AURKAThr288 were observed for the drug combination group, whereas KIF15 levels were noticeably lower. Similarly, enhanced cleaved-PARP expression was observed with the combination treatment. The uncropped blots are shown in Figures S8 and S9. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/37894278 ), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-51843_rabbit-polyclonal-aurora-a-antibody-308202410445515.jpg)
![Western Blot: PARD3/Par3 Antibody [NBP1-88861] - Analysis in human cell lines A-549 and U-251MG. Corresponding RNA-seq data are presented for the same cell lines. Loading control: Anti-GAPDH.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Western-Blot-NBP1-88861-img0017.jpg "<b>Orthogonal Strategies Validation. </b>Western Blot: PARD3/Par3 Antibody [NBP1-88861] - Analysis in human cell lines A-549 and U-251MG. Corresponding RNA-seq data are presented for the same cell lines. Loading control: Anti-GAPDH.")
![<b>Orthogonal Strategies Validation. </b>Simple Western: PARD3/Par3 Antibody [NBP1-88861] - Simple Western lane view shows a specific band for PARD3/Par3 in 0.2 mg/ml of RT-4 lysate. This experiment was performed under reducing conditions using the 66-440 kDa separation system.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Simple-Western-NBP1-88861-img0009.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cell line U-2 OS shows localization to cell junctions. Antibody staining is shown in green.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0016.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining PARD3 in mouse trophoblast stem cells. Verified customer review from 1DegreeBio.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0012.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human colon shows distinct luminal membranous positivity in glandular cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0014.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. In wild-type myotubes PAR3 remains cytoplasmic. MCAM contributes to the establishment of cell autonomous polarity in myogenic and chondrogenic differentiation. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/28923978/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0023.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human skin shows weak to moderate cytoplasmic positivity in epidermal cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0022.jpg)
![Immunocytochemistry/Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cell line 8505C cells (anaplastic thyroid cancer cell line). Image from verified customer review.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-88861-img0013.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human kidney shows weak to moderate membranous positivity in cells in tubules.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0019.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human cerebellum shows moderate positivity in neuropil.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0020.jpg)
![Immunohistochemistry-Paraffin: PARD3/Par3 Antibody [NBP1-88861] - Staining of human fallopian tube shows weak to moderate positivity in luminal membrane in glandular cells.](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Immunohistochemistry-Paraffin-NBP1-88861-img0021.jpg)
![Simple Western: PARD3/Par3 Antibody [NBP1-88861] - Electropherogram image(s) of corresponding Simple Western lane view. PARD3/Par3 antibody was used at 1:100 dilution on RT-4 lysate(s).](http://images.novusbio.com/fullsize/PARD3-Par3-Antibody-Simple-Western-NBP1-88861-img0015.jpg)
![Immunocytochemistry/ Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. (A) In elongating myotubes (10T1/2 cells treated with testosterone for 7 days) VANGL2 is localized asymmetrically at the tip of the cell. (B) The VANGL2 enriched tip of the cell is marked by MSN. (C) In MCAM knockout C164 cells myotube elongation fails, MSN labels the whole plasma membrane & VANGL2 is spread across the cytoplasm. (D) Highly polarized localization of MCAM & SCRIB at the distal end of growing wild-type myotube. Separate channels of the boxed area are shown on the right. (E) In MCAM knockout cells SCRIB levels remain low & it is spread evenly in the cell. (F) In wild-type myotubes PAR3 remains cytoplasmic, whereas (G) in MCAM knockout C164 cells it can be detected at the cell cortex. (H) RT-qPCR demonstrates reduced expression of Scrib in MCAM mutant cell lines. Cells were treated for 7 days with BMP2 or testosterone (n=3; **P<0.01; ***P<0.001; two-tailed t-test; mean±s.e.m.). (I) Deletion of MCAM endocytosis motif leads to similar polarity defects as complete MCAM elimination. VANGL2 is evenly spread in U125 cells & PAR3 accumulates in cell cortex. (J) In chondrogenic differentiation VANGL2 was observed asymmetrically in limited number of cells. In MCAM mutant cell lines (C149, C164, U125) VANGL2 accumulated around the nucleus. (K) Initiation of myogenic (4-day culture with testosterone) & chondrogenic differentiation (4-day culture with BMP2) led to downregulation of ERK1/2 phosphorylation (p-ERK1/2). Instead in MCAM mutant cell lines ERK1/2 phosphorylation increased. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/doi/10.1242/bio.027771/256759/MCAM-contributes-to-the-establishment-of-cell), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88861_rabbit-polyclonal-pard3-par3-antibody-310202416113535.jpg)
![Immunocytochemistry/ Immunofluorescence: PARD3/Par3 Antibody [NBP1-88861] - MCAM is required to establish cell autonomous polarity. (A) In elongating myotubes (10T1/2 cells treated with testosterone for 7 days) VANGL2 is localized asymmetrically at the tip of the cell. (B) The VANGL2 enriched tip of the cell is marked by MSN. (C) In MCAM knockout C164 cells myotube elongation fails, MSN labels the whole plasma membrane & VANGL2 is spread across the cytoplasm. (D) Highly polarized localization of MCAM & SCRIB at the distal end of growing wild-type myotube. Separate channels of the boxed area are shown on the right. (E) In MCAM knockout cells SCRIB levels remain low & it is spread evenly in the cell. (F) In wild-type myotubes PAR3 remains cytoplasmic, whereas (G) in MCAM knockout C164 cells it can be detected at the cell cortex. (H) RT-qPCR demonstrates reduced expression of Scrib in MCAM mutant cell lines. Cells were treated for 7 days with BMP2 or testosterone (n=3; **P<0.01; ***P<0.001; two-tailed t-test; mean±s.e.m.). (I) Deletion of MCAM endocytosis motif leads to similar polarity defects as complete MCAM elimination. VANGL2 is evenly spread in U125 cells & PAR3 accumulates in cell cortex. (J) In chondrogenic differentiation VANGL2 was observed asymmetrically in limited number of cells. In MCAM mutant cell lines (C149, C164, U125) VANGL2 accumulated around the nucleus. (K) Initiation of myogenic (4-day culture with testosterone) & chondrogenic differentiation (4-day culture with BMP2) led to downregulation of ERK1/2 phosphorylation (p-ERK1/2). Instead in MCAM mutant cell lines ERK1/2 phosphorylation increased. Scale bars: 25 µm. Image collected & cropped by CiteAb from the following publication (//journals.biologists.com/bio/article/doi/10.1242/bio.027771/256759/MCAM-contributes-to-the-establishment-of-cell), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-88861_rabbit-polyclonal-pard3-par3-antibody-310202416113539.jpg)
![Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human liver, pancreas, pituitary gland and tonsil using Anti-POU1F1 antibody NBP1-92273 (A) shows similar protein distribution across tissues to independent antibody NBP2-55357 (B).](http://images.novusbio.com/fullsize/Pit1-Antibody-Immunohistochemistry-Paraffin-NBP1-92273-img0009.jpg "<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human liver, pancreas, pituitary gland and tonsil using Anti-POU1F1 antibody NBP1-92273 (A) shows similar protein distribution across tissues to independent antibody NBP2-55357 (B).")
![<b>Independent Antibodies Validation. </b>Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human pituitary gland shows moderate to strong nuclear positivity in neuroendocrine cells in the anterior lobe.](http://images.novusbio.com/fullsize/Pit1-Antibody-Immunohistochemistry-Paraffin-NBP1-92273-img0003.jpg)
![Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human liver shows no positivity in hepatocytes as expected.](http://images.novusbio.com/fullsize/Pit1-Antibody-Immunohistochemistry-Paraffin-NBP1-92273-img0004.jpg)
![Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human tonsil shows no positivity in non-germinal center cells as expected.](http://images.novusbio.com/fullsize/Pit1-Antibody-Immunohistochemistry-Paraffin-NBP1-92273-img0005.jpg)
![Immunohistochemistry-Paraffin: Pit1 Antibody [NBP1-92273] - Staining of human pancreas shows no positivity in exocrine glandular cells as expected.](http://images.novusbio.com/fullsize/Pit1-Antibody-Immunohistochemistry-Paraffin-NBP1-92273-img0006.jpg)
![Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - HELLS expression and protein levels are modulated with YAP1/TEAD inhibition downstream of SHH signaling. Western blot showing protein levels of HELLS, cleaved caspase 3 (CC3), and Cyclin D1 in verteporfin treated CGNPs. Blot is representative of three replicates. Full-length blots are presented in Supplementary Fig. S4. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-50088-1), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Western-Blot-NBP2-32840-img0006.jpg "<b>Biological Strategies Validation. </b>Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - HELLS expression and protein levels are modulated with YAP1/TEAD inhibition downstream of SHH signaling. Western blot showing protein levels of HELLS, cleaved caspase 3 (CC3), and Cyclin D1 in verteporfin treated CGNPs. Blot is representative of three replicates. Full-length blots are presented in Supplementary Fig. S4. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41598-019-50088-1), licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Formalin-paraffin human Mantle Cell Lymphoma stained with Cyclin D1 Ab (Clone SPM587).](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Immunohistochemistry-Paraffin-NBP2-32840-img0004.jpg)
![Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on MCF-7 cells. Black: cells alone; Green: Isotype Control; Red: PE-labeled Cyclin D1 Monoclonal Antibody (SPM587).](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Flow-Cytometry-NBP2-32840-img0008.jpg)
![Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - analysis of Cyclin D1 in human breast cancer cell line MDA-MB-231 cell lysate using anti-Cyclin D1. Image from verified customer review.](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Western-Blot-NBP2-32840-img0003.jpg)
![Western Blot: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Western Blot of cyclin D1 in (1) C2C12 (2) HepG2 & (3) NIH3T3 Lysate with Cyclin D1 Ab (SPM587)](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Western-Blot-NBP2-32840-img0005.jpg)
![Flow Cytometry: Cyclin D1 Antibody (SPM587) [NBP2-32840] - Flow Cytometric analysis of human Cyclin D1 on Jurkat cells. Black: cells alone; Green: Isotype Control; Red: PE-labeled Cyclin D1 Monoclonal Antibody (SPM587).](http://images.novusbio.com/fullsize/Cyclin-D1-Antibody-SPM587-Flow-Cytometry-NBP2-32840-img0007.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0010.jpg "Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Western Blot Analysis of human HeLa cell lysate using p53 Antibody (BP53-12).")
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - p53 was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using a 1 ug/mL mouse anti-p53 monoclonal (NBP2-29453, Novus Biologicals) for 1 hour at room temperature followed by the appropriate HRP polymer reagent, anti-mouse IgG VisUCyte HRP polymer (VC001). Tissue was stained using DAB (brown) and counterstained with hematoxylin (blue).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0008.jpg)
![Western Blot: p53 Antibody (BP53-12) [NBP2-29453] - Analysis of p53 1) A431 2) MCF7 and 3) HEK293 lysate probed with p53 antibody at 1 ug/ml. goat anti-mouse Ig HRP secondary antibody and PicoTect ECL substrate solution were used for this test.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Western-Blot-NBP2-29453-img0001.jpg)
![Immunohistochemistry-Paraffin: p53 Antibody (BP53-12) [NBP2-29453] - Formalin-paraffin human colon carcinoma stained with p53 Ab (BP53-12).](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Immunohistochemistry-Paraffin-NBP2-29453-img0003.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Simple Western lane view shows a specific band for p53 in 0.2 mg/ml of MDA-MB-231 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0004.jpg)
![Simple Western: p53 Antibody (BP53-12) [NBP2-29453] - Electropherogram image of the corresponding Simple western lane view. p53 antibody was used at 10 ug/ml dilution on MDA-MB-231 lysate(s) respectively.](http://images.novusbio.com/fullsize/p53-Antibody-BP53-12-Simple-Western-NBP2-29453-img0005.jpg)
![Immunocytochemistry/Immunofluorescence: MyoD Antibody [NBP1-54153] - RD cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-MyoD at 5 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/MyoD-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-54153-img0005.jpg "Immunocytochemistry/Immunofluorescence: MyoD Antibody [NBP1-54153] - RD cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.5% Triton X-100. The cells were incubated with anti-MyoD at 5 ug/ml overnight at 4C and detected with an anti-rabbit DyLight 488 (Green) at a 1:500 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.")
![Western Blot: MyoD1 Antibody [NBP1-54153] - Detection of MYOD1 in RH30 cells.](http://images.novusbio.com/fullsize/MyoD1-Antibody-Western-Blot-NBP1-54153-img0004.jpg)
![Immunocytochemistry/Immunofluorescence: MyoD Antibody [NBP1-54153] - Staing of MYOD1 in RD cells with FITC (green). Nuclei were counterstained with DAPI (blue).](http://images.novusbio.com/fullsize/MyoD1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-54153-img0003.jpg)
![Immunocytochemistry/ Immunofluorescence: CD81 Antibody (M38) [NBP1-44861] - CD81 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line but is not detected in CD81 knockout (KO) HeLa cell line using Mouse Anti-Human CD81 Monoclonal Antibody (Catalog # NBP1-44861) at 15 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Knockout-Validated-NBP1-44861-img0006.jpg "<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: CD81 Antibody (M38) [NBP1-44861] - CD81 was detected in immersion fixed HeLa human cervical epithelial carcinoma cell line but is not detected in CD81 knockout (KO) HeLa cell line using Mouse Anti-Human CD81 Monoclonal Antibody (Catalog # NBP1-44861) at 15 ug/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Mouse IgG Secondary Antibody (red; Catalog # NL007) and counterstained with DAPI (blue). Specific staining was localized to the plasma membrane.")
![<b>Genetic Strategies Validation. </b>Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Surface staining pattern of human peripheral blood stained using anti-human CD81 (M38) purified antibody (concentration in sample 4 ug/ml) GAM APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0010.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Surface staining of CD81 in human peripheral blood with anti-CD81 (M38) APC-CyTM7.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0001.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Human peripheral blood with anti-CD81 (M38) APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0002.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Human peripheral blood with anti-CD81 (M38) FITC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0003.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Flow Cytometry: CD81 Antibody (M38) [PE] [NBP1-44861PE] - A cell surface stain was performed on THP-1 cells with CD81 antibody (M38) NBP1-44861 (blue) and a matched isotype control NBP2-27287 (orange). Cells were incubated in an antibody dilution of 1:100 for 20 minutes at room temperature. Both antibodies were conjugated to PE. Image using the PE form of this antibody.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0004.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) PE.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0005.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) PE.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0007.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Staining of CD81 in human peripheral blood with anti-CD81 (M38) biotin, streptavidin-APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0008.jpg)
![Flow Cytometry: CD81 Antibody (M38) [NBP1-44861] - Separation of human lymphocytes (red-filled) from neutrophil granulocytes (black-dashed) in flow cytometry analysis (surface staining) of human peripheral whole blood stained using anti-human CD81 (M38) purified antibody (concentration in sample 4 ug/ml) GAM APC.](http://images.novusbio.com/fullsize/CD81-Antibody-M38-Flow-Cytometry-NBP1-44861-img0009.jpg)